{"id":"W2003470917","doi":"10.2174/156800908786733450","title":"Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Memorial Sloan-Kettering Cancer Center","keywords":"Pazopanib; Temsirolimus; Sunitinib; Axitinib; Sorafenib; Everolimus; Medicine; Vascular endothelial growth factor; Cancer research; Renal cell carcinoma; Bevacizumab; Platelet-derived growth factor receptor; Angiogenesis; PI3K/AKT/mTOR pathway; Tyrosine-kinase inhibitor; Growth factor; Pharmacology; Internal medicine; Cancer; Biology; Signal transduction; VEGF receptors; Discovery and development of mTOR inhibitors; Receptor; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925925,0.0005717599,0.001047787,0.001925204,0.0002362193,0.0005714142,0.000572342,0.000659488,0.003108765],"category_scores_gemma":[0.0002769497,0.0001949486,0.0003164164,0.001860165,0.0002683664,0.0007226001,0.0003203685,0.001186891,0.002600553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004855912,"about_ca_system_score_gemma":0.0005881924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009691391,"about_ca_topic_score_gemma":0.002456921,"domain_scores_codex":[0.9998734,0.00002066699,0.00001283828,0.00001572416,0.00006500209,0.00001236086],"domain_scores_gemma":[0.9998934,0.0000354923,0.00001993271,0.000003002177,0.00003327028,0.00001489216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009081895,0.0001531072,0.0001699967,0.006175895,0.00006756833,0.0003299844,0.00004535211,0.0003779928,0.003286691,0.001749289,0.02132307,0.9662302],"study_design_scores_gemma":[0.00005531414,0.000204083,0.001441316,0.001422168,0.00008015224,0.001890573,0.00004483827,0.0001313932,0.000971281,0.001027341,0.9927185,0.00001313584],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003516459,0.9967655,0.0001545567,0.0002032329,0.0001522721,0.00001008844,0.00001571772,0.00001103469,0.002336019],"genre_scores_gemma":[0.001242118,0.9967759,0.0002928189,0.0002000744,0.0001270703,0.000009375524,0.00003381076,0.000001512208,0.001317213],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003108765,"threshold_uncertainty_score":0.01039988,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05341450169617008,"score_gpt":0.340254233950875,"score_spread":0.2868397322547049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}